Is Enbrel Approved for Psoriatic Arthritis?
No, Enbrel (etanercept) is not FDA-approved specifically for psoriatic arthritis (PsA). It is approved for plaque psoriasis, rheumatoid arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis, but PsA falls outside its labeled indications.[1]
Why Do Doctors Sometimes Prescribe It for PsA?
Enbrel is used off-label for PsA because it targets TNF-alpha, a key driver of inflammation in PsA. Clinical studies show it reduces joint pain, swelling, and skin symptoms in PsA patients, with response rates around 50-70% in trials like those published in The Lancet.[2] Rheumatologists prescribe it based on guidelines from the American College of Rheumatology, which list TNF inhibitors like Enbrel as first-line for active PsA.[3]
How Does Enbrel Compare to Approved PsA Treatments?
| Drug | Approved for PsA? | Mechanism | Common Dose |
|------|-------------------|-----------|-------------|
| Enbrel (etanercept) | No (off-label) | TNF inhibitor | 50 mg weekly subQ |
| Humira (adalimumab) | Yes | TNF inhibitor | 40 mg every 2 weeks subQ |
| Cosentyx (secukinumab) | Yes | IL-17 inhibitor | 150-300 mg monthly subQ |
| Tremfya (guselkumab) | Yes | IL-23 inhibitor | 100 mg every 8 weeks subQ |
Enbrel performs similarly to approved TNF blockers in PsA trials but lacks formal approval, potentially affecting insurance coverage.[4]
What Are the Risks and Side Effects in PsA Use?
Infections (e.g., upper respiratory, 30-40% of patients), injection-site reactions (20-37%), and rare serious risks like tuberculosis reactivation or lymphoma occur. PsA patients with skin involvement see psoriasis improvement, but monitoring for hepatosplenic T-cell lymphoma is advised in young males with IBD history.[1][5]
Who Makes Enbrel and What's the Cost?
Amgen and Pfizer co-market Enbrel. List price is about $7,000 per month (50 mg weekly), though patient assistance programs and biosimilars (e.g., Erelzi) lower costs to $1,000-$4,000 with insurance.[6] Check DrugPatentWatch.com for patent details—key U.S. patents expired in 2029, but formulation patents extend to 2029-2034, delaying full generic entry.[7]
When Might Approved Status Change?
No ongoing FDA approval push for PsA is public, but real-world data from registries like Corrona supports its efficacy. Biosimilars could expand access by 2029.[7]
Sources:
[1] FDA Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/103795s5605lbl.pdf
[2] Mease et al., *Lancet* 2004: https://pubmed.ncbi.nlm.nih.gov/15574134/
[3] ACR Guidelines 2018: https://www.rheumatology.org/Portals/0/Files/Psoriatic-Arthritis-Guideline.pdf
[4] Keystone et al., *Ann Rheum Dis* 2005: https://ard.bmj.com/content/64/2/159
[5] Enbrel Safety Data: https://www.enbrel.com/psoriasis
[6] GoodRx Pricing: https://www.goodrx.com/enbrel
[7] DrugPatentWatch: https://www.drugpatentwatch.com/p/tradename/ENBREL